Aimmune Therapeutics Announces Proposed Public Offering of Common Stock
February 20 2018 - 4:16PM
Business Wire
Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical
company developing treatments for potentially life-threatening food
allergies, today announced that it has commenced an underwritten
public offering of up to $150,000,000 of shares of its common
stock. All of the shares to be sold in the offering will be offered
by Aimmune. In addition, Aimmune expects to grant the underwriters
of the offering a 30-day option to purchase up to an additional
$22,500,000 of shares of common stock at the public offering price,
less underwriting discounts and commissions. The offering is
subject to market and other conditions, and there can be no
assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering.
Aimmune currently expects to use the net proceeds from this
offering to fund its ongoing clinical development of AR101, an
investigational biologic for the treatment of patients with peanut
allergy, regulatory activities related to the potential filing of a
Biologics License Application and a Marketing Authorization
Application for AR101, preparation for potential commercialization
of AR101, research and development of additional CODITTM product
candidates, and for general corporate purposes.
BofA Merrill Lynch, Cantor Fitzgerald & Co. and Piper
Jaffray & Co. are acting as joint bookrunning managers for the
offering. Credit Suisse and RBC Capital Markets are also acting as
bookrunning managers.
A registration statement relating to the securities being sold
in this offering was filed with the Securities and Exchange
Commission on February 20, 2018, and was automatically declared
effective upon filing. The offering of these securities is being
made only by means of a prospectus, copies of which may be obtained
from: BofA Merrill Lynch, NC1-004-03, 200 North College Street, 3rd
floor, Charlotte, NC 28255-0001, Attention: Prospectus Department,
email: dg.prospectus_requests@baml.com; or from Cantor Fitzgerald
& Co., Attention: Capital Markets, 499 Park Avenue, 6th Floor,
New York, NY 10022; email: prospectus@cantor.com; or from
Piper Jaffray & Co., Attention: Prospectus Department, 800
Nicollet Mall, J12S03, Minneapolis, MN 55402, via telephone at
800-747-3924 or email at prospectus@pjc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification of these securities under the securities laws of any
such state or jurisdiction.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage
biopharmaceutical company developing treatments for potentially
life-threatening food allergies. The company’s Characterized Oral
Desensitization ImmunoTherapy (CODIT™) approach is intended to
achieve meaningful levels of protection by desensitizing patients
with defined, precise amounts of key allergens. Aimmune’s first
investigational biologic product using CODIT™, AR101 for the
treatment of peanut allergy, has received the FDA’s Breakthrough
Therapy Designation for the desensitization of peanut-allergic
patients 4–17 years of age and is currently being evaluated in
Phase 3 clinical trials.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180220006569/en/
Aimmune Therapeutics, Inc.Investors:Laura Hansen, Ph.D.,
650-396-3814lhansen@aimmune.comorMedia:Alison Marquiss,
650-376-5583amarquiss@aimmune.com
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aimmune Therapeutics (NASDAQ:AIMT)
Historical Stock Chart
From Sep 2023 to Sep 2024